RP215 single chain fragment variable and single domain recombinant antibodies induce cell cycle arrest at G0/G1 phase in breast cancer

Yu, Fang; Wang, Yanling; Xiao, Yun; He, Ying; Luo, Cong; Dong, Diansheng; Li, Chunhong; Xu, Shengsheng; Xiang, Tingxiu

doi:10.1016/j.molimm.2014.01.007

Cited by 8 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other authors have documented the efficacy of a scFv against the CA125 antigen, an overexpressed protein in various solid tumors. Yu et al demonstrated that an anti-CA125 scFv specifically recognized the antigen on breast cancer cells [ 135 ].…”

Section: Applications Of Scfvsmentioning

confidence: 99%

Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy

Muñoz-López

Ribas‐Aparicio

Becerra-Báez

et al. 2022

Cancers

View full text Add to dashboard Cite

Cancer remains a public health problem worldwide. Although conventional therapies have led to some excellent outcomes, some patients fail to respond to treatment, they have few therapeutic alternatives and a poor survival prognosis. Several strategies have been proposed to overcome this issue. The most recent approach is immunotherapy, particularly the use of recombinant antibodies and their derivatives, such as the single-chain fragment variable (scFv) containing the complete antigen-binding domains of a whole antibody that successfully targets tumor cells. This review describes the recent progress made with scFvs as a cancer diagnostic and therapeutic tool, with an emphasis on preclinical approaches and their potential use in clinical trials.

show abstract

Section: Applications Of Scfvsmentioning

confidence: 99%

Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy

Muñoz-López

Ribas‐Aparicio

Becerra-Báez

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…4 immunocomplexes formation (Azzazy and Highsmith, 2002;Zhang et al, 2014;Yu et al, 2014). Castro et al (2014) has described the generation of a recombinant scFv against BaP1 (scFvBaP1) from the venom of the pit viper B. asper, a medically important species in Central America and regions of South and North America.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Expression of an scFv antibody fragment in Nicotiana benthamiana and in vitro assessment of its neutralizing potential against the snake venom metalloproteinase BaP1 from Bothrops asper

Gomes

Álvarez

Quellis

et al. 2019

Toxicon

View full text Add to dashboard Cite

show abstract

“…The first promising intrabody approaches in cancer treatment which have been published in immunotherapy involve the application of single-chain variable fragment (scFv) against human epidermal growth factor receptor 2 (HER2) in breast cancer 17 . Until now, scFv intrabody has been proven to be promising in several types of cancer 18 - 22 . Recently, our group generated the functional intrabody against EMMPRIN (scFv-M6-1B9) and transferred the gene encoding scFv-M6-1B9 intrabody via adenovirus serotype 5 vector (Ad5- scFv-M6-1B9 ) which retained EMMPRIN in ER with the KDEL peptide (ER retention signal) 23 .…”

Section: Introductionmentioning

confidence: 99%

Intracellular Acidosis Promotes Mitochondrial Apoptosis Pathway: Role of EMMPRIN Down-regulation via Specific Single-chain Fv Intrabody

Thammasit¹,

Sangboonruang²,

Suwanpairoj³

et al. 2015

J. Cancer

View full text Add to dashboard Cite

Extracellular matrix metalloproteinase inducer (EMMPRIN) is a human leukocyte surface molecule that is enriched on the surface of many cancer cells, and it plays an important role in proliferation and metastasis. In this study, we utilized the chimeric adenoviral vector Ad5/F35 carrying gene encoding scFv against EMMPRIN (scFv-M6-1B9) to down-regulate EMMPRIN cell surface expression and investigated programmed cell death response in colorectal cancer (CRC) cell, Caco-2. The scFv-M6-1B9 intrabody exhibits robust activity in reducing EMMPRIN cell surface expression. This approach led to the inducing of apoptosis, which was relative to the increasing of apoptotic bodies in sub-G1 peak, phosphatidylserine externalization, as well as TUNEL-positive cells. In addition, real-time RT-PCR and western blotting analysis indicated that apoptosis was enhanced through the mitochondrial pathway, a marked reduction of Bcl-2, leading to the translocation of cytochrome c and also the dramatic activation of caspase-3. Moreover, carcinoembryonic antigen (CEA), a tumor marker for CRC, was found to have significantly diminished in both secreted protein and mRNA levels. In conclusion, these findings suggest that EMMPRIN down-regulation by scFv-M6-1B9 intrabody has great potential in enhancing the efficacy of apoptosis induction through the mitochondrial pathway and in effecting a decline in the CEA level. Thus, its benefits could be applied to project the future prospects for targeted gene therapy and therapeutic application in monitoring colorectal cancer.

show abstract

RP215 single chain fragment variable and single domain recombinant antibodies induce cell cycle arrest at G0/G1 phase in breast cancer

Cited by 8 publications

References 25 publications

Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy

Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy

Expression of an scFv antibody fragment in Nicotiana benthamiana and in vitro assessment of its neutralizing potential against the snake venom metalloproteinase BaP1 from Bothrops asper

Intracellular Acidosis Promotes Mitochondrial Apoptosis Pathway: Role of EMMPRIN Down-regulation via Specific Single-chain Fv Intrabody

Contact Info

Product

Resources

About